Back

Artificial Intelligence quantified prostate specific membrane antigen imaging in metastatic castrate-resistant prostate cancer patients treated with Lutetium-177-PSMA-617

2025-08-12 oncology Title + abstract only
View on medRxiv
Show abstract

PURPOSEThe VISION study1 found that Lutetium-177 (177Lu)-PSMA-617 ("Lu-177") improved overall survival in metastatic castrate resistant prostate cancer (mCRPC). We assessed whether artificial intelligence enhanced PSMA imaging in mCRPC patients starting Lu-177 could identify those with better treatment outcomes. PATIENTS AND METHODSWe conducted a single site, tertiary center, retrospective cohort study in 51 consecutive mCRPC patients treated 2022-2024 with Lu-177. These patients had received m...

Predicted journal destinations